{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-009782","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.378730+00:00","generated_at":"2026-05-24T23:22:57.822007+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lixte reports new pre-clinical data on LB-100 activation and potential biomarker for patient response","bullets":["Enzyme discovered that converts LB-100 to active metabolite endothall, published in BioXriv and Int'l J. Pharmaceutics.","Findings open potential biomarker strategy to identify patients most likely to respond to LB-100.","LB-100 also spontaneously converts via slow hydrolysis; enzymatic conversion inside cell expedites activation.","Clinical trials for LB-100 in ovarian and colorectal cancer continue; CEO says data will help optimize patient selection."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-009782","json":"https://secwatch.observer/filing/0001493152-25-009782.json","markdown":"https://secwatch.observer/filing/0001493152-25-009782.md","text":"https://secwatch.observer/filing/0001493152-25-009782.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225009782/0001493152-25-009782-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225009782/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:22:57.822007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}